

Special Issue

Drug Discovery Targeting the Hippo Signaling Pathway

Message from the Guest Editors

As the role of the Hippo signaling pathway in cancer and tissue regeneration becomes apparent, small molecules that target the components of this pathway are increasingly being developed and tested for their utility in cancer therapy and regenerative medicine. The druggability of kinases is well established; therefore, two core kinases in this pathway, MST1/2 and LATS1/2, are targeted. Interestingly, the TEAD family of transcription factors has emerged as a novel target. This Special Issue aims to attract manuscripts describing hits and screens, which, when disseminated to the community, result in the development of more favorable pharmaceuticals through collective effort. We are also interested in manuscripts that identify novel druggable targets of the Hippo pathway. Topics that highlight other disease indications where Hippo modulators can be used also fall within the scope of this Special Issue.

Guest Editors

Dr. Ajaybabu V. Pobbati

1. Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
2. Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH 44195, USA

Dr. Iris Valtingoer

Sanofi Oncology Research Therapeutic Area, 1, impasse des Ateliers, 94400 Vitry-sur-Seine, France

Deadline for manuscript submissions

closed (28 June 2023)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/134497

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)